Biovitrum is a Swedish pharmaceutical company, based in Stockholm, Sweden and Cambridge, UK.

Contents 1 History 2 Company 3 External links 4 References

[edit] History

Biovitrum was created in 2001 as a spinoff from Pharmacia Corp. in the wake of the merger between the parent company Pharmacia and Upjohn and Monsanto Company in 1999. Since its creation, the company has gone through multiple transitions from a research intensive and diversified company to the current entity, focused on niche pharmaceuticals and specialist medical care. Its plasma product division was sold in 2002 to Octapharma. Biovitrum retained its recombinant factor VIII product, Refacto, which has been a major source of revenue during the company's early consolidation phase. In 2005, Biovitrum acquired the Swedish biotech company Arexis and the British company Cambridge Biotechnology Ltd, strengthening its portfolio in bio-pharmaceuticals and clinical projects. The company's in-house research effort has been reduced over the years and it is now more reliant on in-licensing for its project portfolio management.

[edit] Company

Biovitrum is a publicly traded company as of autumn 2006 and listed on the OMX Nordic stock exchange. The company currently employs approximately 500 people and has annual revenues of 1.2 billion Swedish krona.

[edit] External links

• "Biovitrum home page"

[edit] References

• "comment on Biovitrum IPO"